REVIEW

Recent advances in understanding the biology of marginal zone lymphoma [version 1; peer review: 2 approved]

Francesco Bertoni^{1,2*}, Davide Rossi^{1,2*}, Emanuele Zucca^{1,2}

¹Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland

²Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland

* Equal contributors

V1 First published: 28 Mar 2018, 7(F1000 Faculty Rev):406
<https://doi.org/10.12688/f1000research.13826.1>

Latest published: 28 Mar 2018, 7(F1000 Faculty Rev):406
<https://doi.org/10.12688/f1000research.13826.1>

Abstract

There are three different marginal zone lymphomas (MZLs): the extranodal MZL of mucosa-associated lymphoid tissue (MALT) type (MALT lymphoma), the splenic MZL, and the nodal MZL. The three MZLs share common lesions and deregulated pathways but also present specific alterations that can be used for their differential diagnosis. Although trisomies of chromosomes 3 and 18, deletions at 6q23, deregulation of nuclear factor kappa B, and chromatin remodeling genes are frequent events in all of them, the three MZLs differ in the presence of recurrent translocations, mutations affecting the NOTCH pathway, and the transcription factor Kruppel like factor 2 (*KLF2*) or the receptor-type protein tyrosine phosphatase delta (*PTPRD*). Since a better understanding of the molecular events underlying each subtype may have practical relevance, this review summarizes the most recent and main advances in our understanding of the genetics and biology of MZLs.

Keywords

marginal zone lymphoma, genetics and biology of MZLs, extranodal MZL of MALT type, splenic MZL, nodal MZL

Open Peer Review

Approval Status

	1	2
version 1
28 Mar 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Lugui Qiu**, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
2. **Theodoros P Vassilakopoulos**, National and Kapodistrian University, Laikon General Hospital, Athens, Greece

Any comments on the article can be found at the end of the article.

Corresponding author: Emanuele Zucca (ielsg@eoc.ch)

Author roles: **Bertoni F:** Conceptualization, Investigation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Rossi D:** Conceptualization, Investigation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Zucca E:** Conceptualization, Investigation, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Bertoni F *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Bertoni F, Rossi D and Zucca E. **Recent advances in understanding the biology of marginal zone lymphoma [version 1; peer review: 2 approved]** F1000Research 2018, 7(F1000 Faculty Rev):406 <https://doi.org/10.12688/f1000research.13826.1>

First published: 28 Mar 2018, 7(F1000 Faculty Rev):406 <https://doi.org/10.12688/f1000research.13826.1>

Introduction

In the World Health Organization classification, there are three different marginal zone lymphoma (MZL) entities with specific diagnostic criteria, behavior, and therapeutic implications: the extranodal MZL of mucosa-associated lymphoid tissue (MALT) type (MALT lymphoma), the splenic MZL (SMZL), and the nodal MZL (NMZL)¹. MALT lymphoma is the commonest MZL type, accounting for 5 to 8% of all B-cell lymphomas^{2,3}. Their differential diagnosis is not straightforward in the non-rare cases presenting with disseminated disease involving lymph nodes, spleen, peripheral blood, bone marrow, or other extranodal sites. A better understanding of the molecular events underlying each subtype may have practical relevance.

MZLs are believed to derive from B cells of the “marginal zone”, the external part of the secondary lymphoid follicles. The marginal zone is more evident in the lymphatic tissues continuously exposed to external antigens, such as the mesenteric lymph nodes, the MALT, and the spleen. Marginal zone B cells act as innate-like lymphocytes able to mount rapid antibody responses to both T cell-dependent and T cell-independent antigens, mostly the latter⁴.

The three MZLs clearly share common lesions and deregulated pathways, but they also present specific alterations that can be used for their differential diagnosis^{5–24} (Figure 1). Trisomies of chromosomes 3 and 18 and deletions at 6q23 are frequent events in all MZLs, as well as somatic mutations of genes coding for proteins involved in chromatin remodeling^{5–7,25–28}. The activation of the nuclear factor kappa B (NF-κB) pathway is also common to all three entities, generally via somatic mutations or deletions (or both) of *TNFAIP3* (A20) at 6q23^{5–7,25–27,29–33}. Mutations affecting the NOTCH pathway and the transcription factor *KLF2* are present in both SMZL and NMZL^{6,7}. Whereas SMZL is specifically characterized by deletions of

chromosome 7q, NMZL shows inactivation of *PTPRD* and a much higher prevalence of mutations affecting *KMT2D* (MLL2)^{6,7,32,33}. Unlike the vast majority of other B-cell lymphomas, SMZL and NMZL do not present specific recurrent chromosomal translocations, while these are detected in MALT lymphomas, in which at least three of them activate the NF-κB pathway^{8–14,16,34,35} (Figure 1).

We will now highlight the most recent and main advances in our understanding of the genetics and biology of MZLs.

NF-κB signaling

Active NF-κB signaling is necessary for the generation and maintenance of normal marginal zone B cells and this requires weak B-cell receptor (BCR) signaling (for example, started by auto-antigens and leading to canonical NF-κB pathway activation) or CD40 signaling, activating the non-canonical NF-κB pathway^{36,37}. Following BCR engagement, Src family kinases phosphorylate the cytoplasmic ITAM portions of CD79A and CD79B^{38–45}. The latter bind the tyrosine kinase SYK and start a signaling cascade that, via the Bruton's tyrosine kinase (BTK), results in phosphorylation and activation of CARD11. CARD11, BCL10, and MALT1 form the CBM signaling complex linking BCR signaling to the canonical NF-κB pathway. Upon phosphorylation, CARD11 acquires an open conformation, allowing the recruitment of CARD11 to MALT1 and BCL10 into the CBM complex and activate the IκBKB kinase. IκBKB phosphorylates the IκBα inhibitor molecule, causing its proteasome-mediated degradation. Finally, the NF-κB complexes (mainly p50/RelA and p50/c-Rel dimers) can enter the nucleus and act as transcriptional factors. TNFAIP3 negatively regulates the whole pathway, adding and subtracting ubiquitin moieties to different NF-κB signaling pathways. Binding of CD40 activates the non-canonical NF-κB pathway. Following disruption of a negative regulatory complex comprising

Figure 1. Summary of the main genetic and biologic features characterizing marginal zone lymphomas. ^Depending on the anatomical site. BCR, B-cell receptor; IGHV, immunoglobulin heavy variable; MALT, mucosa-associated lymphoid tissue; NF-κB, nuclear factor kappa B; NMZL, nodal marginal zone lymphoma; SMZL, splenic marginal zone lymphoma; TLR, Toll-like receptor.

TRAF3/MAP3K14-TRAF2/BIRC3, the MAP3K14 kinase (also known as NIK) phosphorylates NF- κ B2 (p100), causing its proteasomal processing and the formation of p52-containing NF- κ B dimers. In particular, BIRC3 (cIAP2), owing to its C-terminal RING domain, has ubiquitin ligase (E3) activity⁴⁶ and leads to BCL10 and MAP3K14 ubiquitination⁴⁶. Similarly, TRAF3 induces MAP3K14 degradation by recruiting it to the BIRC3 ubiquitin ligase complex. The p52 protein dimerizes with RelB to translocate into the nucleus, acting as a transcriptional factor.

In all of the MZLs, both canonical NF- κ B signaling and non-canonical NF- κ B signaling are deregulated by genetic events. The most frequent event is the inactivation, by deletions or mutations, of its negative regulator encoded by the *TNFAIP3* (A20) gene^{5,6,25–27,29–31,47}. Three other NF- κ B signaling components—*MALT1*, *BCL10*, and *BIRC3*—are involved in the three most recurrent MALT lymphoma translocations: the t(11;18)(q21;q21), the t(14;18)(q32;q21), and the (1;14)(p22;q32)^{46,48}. The t(11;18) translocation creates the BIRC3-MALT1 fusion protein, in which BIRC3 always lacks its RING domain; thus, BIRC3-MALT1 can bind BCL10 through the BIR domains of BIRC3 but no longer ubiquitinates BCL10⁴⁶. BIRC3-MALT1 can also mediate the proteolytic cleavage of MAP3K14, thereby triggering the non-canonical NF- κ B pathway⁴⁹. The t(11;18) is the most frequent chromosomal translocation in MALT lymphomas, detected in 15 to 50% of cases, more commonly in gastric and pulmonary MALT lymphomas^{13,50,51}. SMZL and NMZL present recurrent mutations of the *BIRC3* gene in about 10% and 5% of cases, respectively^{6,31,52}. These mutations disrupt the same RING domain that is removed by the t(11;18) in MALT lymphomas, and the mutated BIRC3 is no longer able to inactivate MAP3K14 via ubiquitination^{31,53}. *TRAF3* is also inactivated in about 5% of SMZL and NMZL cases by mutations leading to the loss of its C-terminal MATH domain necessary for the MAP3K14 docking site and recruitment to BIRC3 degradation^{6,31}.

The t(14;18) translocation occurs in 15 to 20% of MALT lymphomas, more frequently in non-gastrointestinal sites such as lung and ocular adnexa, and brings the intact *MALT1* gene under the control of the *IGH* enhancer, resulting in deregulated expression of *MALT1* directly contributing to NF- κ B activation^{10,54}. The t(1;14) translocation and its variant t(1;2)(p22;p12) occur in 1 to 2% of MALT lymphomas⁵⁵. Similarly to the t(14;18), the entire coding region of *BCL10* is moved under the control of the *IGH* enhancer region (or the *IGLk* region in the case of a variant translocation) and has a direct effect on the NF- κ B signaling⁵⁶.

The important role of BIRC3-MALT1 fusion protein, as well as MALT1 and BCL10 upregulation, in MALT lymphoma is further underlined by mouse models with development of MALT lymphomas and DLBCL in *MALT1* gene transgenic mice⁵⁷, expansion of marginal zone cells in *BIRC3-MALT1*^{18,35}, and BCL10 transgenic mice⁵⁸.

In SMZL and NMZL, NF- κ B signaling is also sustained by mutations occurring in genes coding members of upstream pathways, such as Toll-like receptor (TLR) and BCR signaling.

MYD88 is an adaptor protein necessary for propagating the TLR downstream signal. MYD88 has a modular structure with an N-terminus death domain (DD), an intermediate linker domain (ID), and a C-terminus TIR domain. The DD allows the creation of a multimeric complex, via the oligomerization and interaction with the serine-threonine kinases IRAK1–4, which activate the NF- κ B. *MYD88* is affected by somatic mutations in 15% of SMZLs and 10% of NMZLs and MALT lymphomas. *MYD88* mutations affect a conserved beta-beta loop of the protein TIR domain^{26,33,59–69} and lead to spontaneous and uncontrolled MYD88/IRAK complex formation⁵⁹. Components of the BCR pathway are also mutated, but almost exclusively in the SMZL and NMZL^{6,25–27,32,33,52,70}, including *CARD11*, which links the BCR to NF- κ B, in 5 to 10% of cases^{6,25–27,31–33,52,60,70}. *CARD11* mutations cause spontaneous protein multimerization and association with CBM complex components (for example, BCL10) with IKK β kinase-mediated NF- κ B activation⁷¹.

NOTCH signaling

Similarly to NF- κ B signaling, NOTCH activation is important for marginal zone differentiation and homing of B cells to the splenic marginal zone^{72–74}. The *NOTCH2* gene is mutated in 10 to 25% of SMZLs, in about 25% of NMZLs, and in less than 5% of MALT lymphomas^{6,32,33,52,68,75,76}. *NOTCH1* is also mutated in about 5% of SMZLs but not at all or at a much lower frequency in NMZL and MALT lymphomas^{6,77}. Negative regulators of NOTCH signaling (such as *SPEN*, *DTX1*, and *MAML2*) are also mutated, though at lower frequency, bringing NOTCH activation by genetic events to 40% of SMZLs and NMZLs^{6,32,52}. NOTCH2 and NOTCH1 are heterodimeric transmembrane proteins that, after binding with their ligands, undergo a cleavage of their intracellular portions, which, once in the nucleus, regulate gene expression via binding with transcriptional co-factors^{78,79}. Importantly, *NOTCH1* and *NOTCH2* mutations cluster in the C-terminal PEST domain and cause a protein truncation with loss of the region necessary for inactivation via proteasomal degradation. Thus, mutations are believed to enhance the stability of the active NOTCH intracellular domains (NICDs) once it has been triggered by microenvironmental interactions⁸⁰.

KLF2

Inactivating mutations in the *KLF2* gene are very frequent in SMZL (20–40%) and NMZL (20% of cases)^{52,81,82}. *KLF2* is a transcription factor, and mice with a B cell-specific deletion of *KLF2* have an increased number of splenic marginal zone B cells⁸³. In lymphoma cells, mutated *KLF2* delocalizes from the nucleus into the cytoplasm and is not able to inhibit the NF- κ B signaling activated by upstream pathways, including the BCR and TLR pathways⁸².

PTPRD

PTPRD is a receptor-type protein tyrosine phosphatase expressed in normal germinal center B cells and, at lower levels, in marginal zone B cells⁵². Almost exclusively in NMZL, *PTPRD* is inactivated by mutations or deletions in about 20% of cases⁵². *PTPRD* regulates many biologic pathways, and

NMZL cases with mutated *PTPRD* appear to have an increased cell proliferation, indicating an involvement of *PTPRD* in cell proliferation⁵².

Chromatin remodeling and epigenome regulation

As a whole, mutations in genes coding for epigenetic regulators are found in about 40% of MZLs. Although their precise consequences in MZL cells are still unknown, mutations in genes such as *KMT2D* (*MLL2*), *SIN3A*, *ARID1A*, *EP300*, *CREBBP*, and *TBL1XR1* highlight a deregulation of the epigenome in all three MZLs^{6,26,33,52,68,76,84}. The importance of epigenetic changes is also underlined by methylation changes described in SMZL, which associate with silencing of different tumor suppressor genes and over-expression of genes involved in BCR/PI3K/AKT/NF- κ B signaling, PRC2-complex (*EZH2*, *EED*, and *SUZ12*), and *MYC* and *IRF4* targets. Clinically, epigenetic changes in SMZL associate with inferior outcome and risk of transformation to a diffuse large B-cell lymphoma (DLBCL)⁸⁵. In MALT lymphomas, promoter methylation seems to increase with a continuum from MALT lymphoma, to MALT lymphoma with large cell component, to DLBCL. Consistently, a series of tumor suppressor genes such as *CDKN2A*, *DAPK1*, *CDH1*, and *TNFAIP3* are silenced via promoter methylation in MALT lymphoma progression^{86–88}.

Antigen stimulation

There is a lot of evidence supporting the notion that antigen stimulation is important for the development and progression of MZLs. MALT lymphoma arises from B cells within populations of immune cells induced by a chronic inflammation taking place in extranodal sites in organs that are physiologically devoid of germinal centers. The most frequent site of MALT lymphoma is the stomach, where the disease has been very clearly associated with the chronic gastritis induced by *Helicobacter pylori*⁸⁹. MALT lymphomas arising in other anatomical sites have also been associated with additional infectious agents, although the etiologic link is not as strong as for the gastric localization and *H. pylori*⁸⁹. These include *Clamydophila psittaci* in orbital adnexa MALT lymphoma^{90–97}, *Borrelia burgdorferi* in cutaneous MALT lymphoma^{98–100}, *Campylobacter jejuni* in immunoproliferative small intestine disease^{101,102}, *Achromobacter xylosoxidans* in pulmonary MALT lymphoma¹⁰³, and hepatitis C virus (HCV) in all MZLs^{104–108}. Besides infection, chronic inflammations in the context of autoimmune disorders, such as Sjögren syndrome or Hashimoto's thyroiditis, are strongly associated with the development of MALT lymphomas affecting salivary glands and thyroid, respectively^{109–117}. Besides the continuous antigenic stimulation, oncogenic events, such as those presented above, contribute to lymphoma growth and progression up to the development of frank tumor independent of the antigenic drive⁸⁹.

MZLs present somatically mutated immunoglobulin heavy variable (IGHV) genes in nearly all cases with a pattern of somatic hypermutation and rearrangements indicative of an antigen selection^{118–125}. The presence of the so-called ongoing mutations (intraclonal variation) and the biased usage of some IGHV segments indicate that the expansion of lymphoma cells could still be antigen-driven. In MALT lymphomas, there is an

apparently biased usage of different IGHV families in cases derived from different anatomical sites or with particular clinical and genetic features: IGHVH1-69 in salivary gland lymphomas, IGHVH3-30 or IGHVH3-23 in gastric MALT lymphomas responsive to *H. pylori* eradication and without the t(11;18) translocation, IGHVH4-34 in orbital adnexal lymphomas, IGHV3 and IGHV4 families in pulmonary lymphomas, and IGHVH1-69 or IGHVH4-59 in cutaneous lymphomas¹²⁶. Similarly, a biased IGHV usage is present in SMZL with a stereotyped BCR in about 10% of cases¹²⁷ and a biased usage of the *IGHV 1-2*04* allele in about 30% of cases^{123,127–130} and in NMZL with a biased usage of the *IGHV4-34* gene in 20 to 30% of cases^{131,132}. IGHVH1-69 is also frequently detected in HCV-related MZLs, similarly to what observed in other HCV-related B-cell expansions such as in the monoclonal rheumatoid factor-like IgM component of the type II mixed cryoglobulinemia, and in monoclonal paraproteins from patients with HCV infection^{106–108,133}. Finally, the antibodies expressed by MALT lymphoma and SMZL cells often recognize self-antigens^{134–136}.

Clinical implications

Molecular lesions may be of help to inform MZL diagnosis, prognosis, and therapeutic targeting. In general, the presence of trisomies of 3 and 18 as single lesions or associated only with *TNFAIP3* loss or 7q deletions is highly indicative of MZL more than other small cell lymphomas. The presence of translocations affecting *MALT1* and *BIRC3* is basically exclusive to MALT lymphoma, in which they are associated with lower response rate to antibiotics treatment. From a diagnostic standpoint, *NOTCH2* mutations are highly specific for SMZL and NMZL among mature B-cell tumors, including conditions that look alike, thus representing a biomarker with positive predictive value for non-MALT MZL specification. Within non-MALT MZL, *PTPRD* mutations are enriched in NMZL and thus may represent a genetic biomarker that, though not highly sensitive, is provided with a positive predictive value for NMZL specification.

From a prognostic standpoint, *KLF2* mutations and *NOTCH2* mutations represent promising prognostic biomarkers associated with poor survival and transformation to aggressive lymphoma whose broad application in clinical practice requires the assessment of whether their incorporation into the currently available clinical prognostic models improves risk stratification of patients.

Molecular aspects of MZL point to deregulated cellular programs worth exploring as therapeutic targets. Pharmacologic interference of NOTCH signaling, non-canonical NF- κ B signaling, or upstream pathways that are connected to NF- κ B, including BCR signaling, are attractive approaches in these lymphomas.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

1. Swerdlow SH, Campo E, Harris NL, *et al.* editors: **WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues**. Lyon, France: IARC Press; 2017; 585. [Reference Source](#)
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood*. 1997; 89(11): 3909–18. [PubMed Abstract](#)
3. Olszewski AJ, Castillo JJ: **Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database**. *Cancer*. 2013; 119(3): 629–38. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Cerutti A, Cols M, Puga I: **Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes**. *Nat Rev Immunol*. 2013; 13(2): 118–32. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Rinaldi A, Mian M, Chigrinova E, *et al.*: **Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome**. *Blood*. 2011; 117(5): 1595–604. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Rossi D, Trifonov V, Fangazio M, *et al.*: **The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development**. *J Exp Med*. 2012; 209(9): 1537–51. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Spina V, Khiabani H, Brusca G, *et al.*: **The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes**. *Blood*. 2014; 124: 705. [Reference Source](#)
8. Dierlamm J, Baens M, Wlodarska I, *et al.*: **The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas**. *Blood*. 1999; 93(11): 3601–9. [PubMed Abstract](#)
9. Willis TG, Jadayel DM, Du MQ, *et al.*: **Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types**. *Cell*. 1999; 96(1): 35–45. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Streubel B, Lamprecht A, Dierlamm J, *et al.*: **T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma**. *Blood*. 2003; 101(6): 2335–9. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Streubel B, Vinatzer U, Lamprecht A, *et al.*: **T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma**. *Leukemia*. 2005; 19(4): 652–8. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Remstein ED, Dogan A, Einerson RR, *et al.*: **The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America**. *Am J Surg Pathol*. 2006; 30(12): 1546–53. [PubMed Abstract](#) | [Publisher Full Text](#)
13. Ye H, Liu H, Attygalle A, *et al.*: **Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma**. *Blood*. 2003; 102(3): 1012–8. [PubMed Abstract](#) | [Publisher Full Text](#)
14. Murga Penas EM, Hinz K, Röser K, *et al.*: **Translocations t(11;18)(q21;q21) and t(14;18)(q32;q21) are the main chromosomal abnormalities involving MLT/ MALT1 in MALT lymphomas**. *Leukemia*. 2003; 17(11): 2225–9. [PubMed Abstract](#) | [Publisher Full Text](#)
15. Ye H, Liu H, Raderer M, *et al.*: **High incidence of t(11;18)(q21;q21) in Helicobacter pylori-negative gastric MALT lymphoma**. *Blood*. 2003; 101(7): 2547–50. [PubMed Abstract](#) | [Publisher Full Text](#)
16. Goatly A, Bacon CM, Nakamura S, *et al.*: **FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control**. *Mod Pathol*. 2008; 21(7): 902–11. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Liu H, Ye H, Ruskone-Fourmestraux A, *et al.*: **T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication**. *Gastroenterology*. 2002; 122(5): 1286–94. [PubMed Abstract](#) | [Publisher Full Text](#)
18. Sagaert X, de Paep P, Libbrecht L, *et al.*: **Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma**. *J Clin Oncol*. 2006; 24(16): 2490–7. [PubMed Abstract](#) | [Publisher Full Text](#)
19. Haralambieva E, Adam P, Ventura R, *et al.*: **Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation**. *Leukemia*. 2006; 20(7): 1300–3. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Dierlamm J, Pittaluga S, Wlodarska I, *et al.*: **Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features**. *Blood*. 1996; 87(1): 299–307. [PubMed Abstract](#)
21. Kwee I, Rancoita PM, Rinaldi A, *et al.*: **Genomic profiles of MALT lymphomas: variability across anatomical sites**. *Haematologica*. 2011; 96(7): 1064–6. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Baens M, Finalet Ferreira J, Tousseyn T, *et al.*: **t(X;14)(p11;q32.33) is recurrent in marginal zone lymphoma and up-regulates GPR34**. *Haematologica*. 2012; 97(2): 184–8. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Ansell SM, Akasaka T, McPhail E, *et al.*: **t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth**. *Blood*. 2012; 120(19): 3949–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Vinatzer U, Gollinger M, Müllauer L, *et al.*: **Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3**. *Clin Cancer Res*. 2008; 14(20): 6426–31. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Jung H, Yoo HY, Lee SH, *et al.*: **The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP**. *Oncotarget*. 2017; 8(10): 17038–49. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Johansson P, Klein-Hitpass L, Gräbell F, *et al.*: **Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas**. *Oncotarget*. 2016; 7(38): 62627–39. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Moody S, Escudero-Ibarz L, Wang M, *et al.*: **Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma**. *J Pathol*. 2017; 243(1): 3–8. [PubMed Abstract](#) | [Publisher Full Text](#)
28. Callet-Bauchu E, Baseggio L, Felman P, *et al.*: **Cytogenetic analysis delineates a spectrum of chromosomal changes that can distinguish non-MALT marginal zone B-cell lymphomas among mature B-cell entities: a description of 103 cases**. *Leukemia*. 2005; 19(10): 1818–23. [PubMed Abstract](#) | [Publisher Full Text](#)
29. Novak U, Rinaldi A, Kwee I, *et al.*: **The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas**. *Blood*. 2009; 113(20): 4918–21. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | **F1000 Recommendation**
30. Honma K, Tsuzuki S, Nakagawa M, *et al.*: **TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas**. *Blood*. 2009; 114(12): 2467–75. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Rossi D, Deaglio S, Dominguez-Sola D, *et al.*: **Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma**. *Blood*. 2011; 118(18): 4930–4. [PubMed Abstract](#) | [Publisher Full Text](#)
32. Kiel MJ, Velusamy T, Betz BL, *et al.*: **Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma**. *J Exp Med*. 2012; 209(9): 1553–65. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Parry M, Rose-Zerilli MJ, Ljungström V, *et al.*: **Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing**. *Clin Cancer Res*. 2015; 21(18): 4174–83. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Jost PJ, Ruland J: **Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications**. *Blood*. 2007; 109(7): 2700–7. [PubMed Abstract](#) | [Publisher Full Text](#)
35. Baens M, Fevery S, Sagaert X, *et al.*: **Selective expansion of marginal zone B cells in Emicro-API2-MALT1 mice is linked to enhanced IκB kinase gamma polyubiquitination**. *Cancer Res*. 2006; 66(10): 5270–7. [PubMed Abstract](#) | [Publisher Full Text](#)
36. Allman D, Pillai S: **Peripheral B cell subsets**. *Curr Opin Immunol*. 2008; 20(2): 149–57. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Spina V, Rossi D: **NF-κB deregulation in splenic marginal zone lymphoma**. *Semin Cancer Biol*. 2016; 39: 61–7. [PubMed Abstract](#) | [Publisher Full Text](#)
38. Lim KH, Staudt LM: **Toll-like receptor signaling**. *Cold Spring Harb Perspect Biol*. 2013; 5(1): a011247. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Staudt LM: **Oncogenic activation of NF-κB**. *Cold Spring Harb Perspect Biol*. 2010; 2(6): a000109. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Yang Y, Staudt LM: **Protein ubiquitination in lymphoid malignancies**. *Immunol Rev*. 2015; 263(1): 240–56. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Pasqualucci L, Zhang B: **Genetic drivers of NF-κB deregulation in diffuse**

- large B-cell lymphoma. *Semin Cancer Biol.* 2016; 39: 26–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
42. **F** Krappmann D, Vincendeau M: **Mechanisms of NF- κ B deregulation in lymphoid malignancies.** *Semin Cancer Biol.* 2016; 39: 3–14.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 43. **F** Zhang Q, Lenardo MJ, Baltimore D: **30 Years of NF- κ B: A Blossoming of Relevance to Human Pathobiology.** *Cell.* 2017; 168(1–2): 37–57.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 44. Samelson LE: **Immunoreceptor signaling.** *Cold Spring Harb Perspect Biol.* 2011; 3(12): pii: a011510.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. **F** Haiflinger S, Nogai H, Pelzer C, *et al.*: **Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines.** *Proc Natl Acad Sci U S A.* 2011; 108(35): 14596–601.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 46. Hu S, Du MQ, Park SM, *et al.*: **cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas.** *J Clin Invest.* 2006; 116(1): 174–81.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Honma K, Tsuzuki S, Nakagawa M, *et al.*: **TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma.** *Genes Chromosomes Cancer.* 2008; 47(1): 1–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Ho L, Davis RE, Conne B, *et al.*: **MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells.** *Blood.* 2005; 105(7): 2891–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. **F** Rosebeck S, Madden L, Jin X, *et al.*: **Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation.** *Science.* 2011; 331(6016): 468–72.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 50. Bertoni F, Coiffier B, Salles G, *et al.*: **MALT lymphomas: pathogenesis can drive treatment.** *Oncology (Williston Park).* 2011; 25(12): 1134–42, 1147.
[PubMed Abstract](#)
 51. **F** Streubel B, Chott A, Huber D, *et al.*: **Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas.** *N Engl J Med.* 2004; 351(3): 250–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 52. Spina V, Khiabanian H, Messina M, *et al.*: **The genetics of nodal marginal zone lymphoma.** *Blood.* 2016; 128(10): 1362–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. **F** Rahal R, Frick M, Romero R, *et al.*: **Pharmacological and genomic profiling identifies NF- κ B-targeted treatment strategies for mantle cell lymphoma.** *Nat Med.* 2014; 20(1): 87–92.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 54. Remstein ED, Kurtin PJ, Einerson RR, *et al.*: **Primary pulmonary MALT lymphomas show frequent and heterogeneous cytogenetic abnormalities, including aneuploidy and translocations involving API2 and MALT1 and IGH and MALT1.** *Leukemia.* 2004; 18(1): 156–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 55. Achuthan R, Bell SM, Leek JP, *et al.*: **Novel translocation of the BCL10 gene in a case of mucosa associated lymphoid tissue lymphoma.** *Genes Chromosomes Cancer.* 2000; 29(4): 347–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Thome M: **CARMA1, BCL-10 and MALT1 in lymphocyte development and activation.** *Nat Rev Immunol.* 2004; 4(5): 348–59.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. **F** Vicente-Dueñas C, Fontán L, Gonzalez-Herrero I, *et al.*: **Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice.** *Proc Natl Acad Sci U S A.* 2012; 109(26): 10534–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 58. Li Z, Wang H, Xue L, *et al.*: **Emu-BCL10 mice exhibit constitutive activation of both canonical and noncanonical NF-kappaB pathways generating marginal zone (MZ) B-cell expansion as a precursor to splenic MZ lymphoma.** *Blood.* 2009; 114(19): 4158–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. **F** Ngo VN, Young RM, Schmitz R, *et al.*: **Oncogenically active MYD88 mutations in human lymphoma.** *Nature.* 2011; 470(7332): 115–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 60. Yan Q, Huang Y, Watkins AJ, *et al.*: **BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.** *Haematologica.* 2012; 97(4): 595–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. Gachard N, Parrens M, Soubeyran I, *et al.*: **IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.** *Leukemia.* 2013; 27(1): 183–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 62. Xu L, Hunter ZR, Yang G, *et al.*: **MYD88 L265P in Waldenström**
macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. *Blood.* 2013; 121(11): 2051–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Trøen G, Warsame A, Delabie J: **CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma.** *ISRN Oncol.* 2013; 2013: 252318.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Li Z, Rinaldi A, Cavalli A, *et al.*: **MYD88 somatic mutations in MALT lymphomas.** *Br J Haematol.* 2012; 158(5): 662–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Varettoni M, Arcaini L, Zibellini S, *et al.*: **Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms.** *Blood.* 2013; 121(13): 2522–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Hamadeh F, MacNamara SP, Aguilera NS, *et al.*: **MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.** *Mod Pathol.* 2015; 28(4): 564–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Martinez-Lopez A, Curiel-Olmo S, Mollejo M, *et al.*: **MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.** *Am J Surg Pathol.* 2015; 39(5): 644–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Martínez N, Almaraz C, Vaqué JP, *et al.*: **Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.** *Leukemia.* 2014; 28(6): 1334–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
 69. Peveling-Oberhag J, Wolters F, Döring C, *et al.*: **Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations.** *BMC Cancer.* 2015; 15: 773.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. Yan Q, Wang M, Moody S, *et al.*: **Distinct involvement of NF- κ B regulators by somatic mutation in ocular adnexal malt lymphoma.** *Br J Haematol.* 2013; 160(6): 851–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. **F** Lenz G, Davis RE, Ngo VN, *et al.*: **Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.** *Science.* 2008; 319(5870): 1676–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 72. Descatoire M, Weller S, Irtan S, *et al.*: **Identification of a human splenic marginal zone B cell precursor with NOTCH2-dependent differentiation properties.** *J Exp Med.* 2014; 211(5): 987–1000.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 73. Witt CM, Won WJ, Hurez V, *et al.*: **Notch2 haploinsufficiency results in diminished B1 B cells and a severe reduction in marginal zone B cells.** *J Immunol.* 2003; 171(6): 2783–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Moran ST, Cariappa A, Liu H, *et al.*: **Synergism between NF-kappa B1/p50 and Notch2 during the development of marginal zone B lymphocytes.** *J Immunol.* 2007; 179(1): 195–200.
[PubMed Abstract](#) | [Publisher Full Text](#)
 75. Bruscaggini A, Monti S, Arcaini L, *et al.*: **Molecular lesions of signalling pathway genes in clonal B-cell lymphocytosis with marginal zone features.** *Br J Haematol.* 2014; 167(5): 718–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
 76. Parry M, Rose-Zerilli MJ, Gibson J, *et al.*: **Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma.** *PLoS One.* 2013; 8(12): e83244.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 77. Mensah AA, Rinaldi A, Ponzoni M, *et al.*: **Absence of NOTCH1 gene mutations in MALT lymphomas.** *Br J Haematol.* 2012; 157(3): 382–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 78. **F** Bray SJ: **Notch signalling in context.** *Nat Rev Mol Cell Biol.* 2016; 17(11): 722–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 79. **F** Brzozowa-Zasada M, Piecuch A, Michalski M, *et al.*: **Notch and its oncogenic activity in human malignancies.** *Eur Surg.* 2017; 49(5): 199–209.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 80. Arruga F, Gizdic B, Serra S, *et al.*: **Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.** *Leukemia.* 2014; 28(5): 1060–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Piva R, Deaglio S, Famà R, *et al.*: **The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma.** *Leukemia.* 2015; 29(2): 503–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Clipson A, Wang M, de Leval L, *et al.*: **KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.** *Leukemia.* 2015; 29(5): 1177–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. Winkelmann R, Sandrock L, Porstner M, *et al.*: **B cell homeostasis and plasma cell homing controlled by Krüppel-like factor 2.** *Proc Natl Acad Sci U S A.* 2011; 108(2): 710–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Cani AK, Soliman M, Hovelson DH, *et al.*: **Comprehensive genomic profiling of**

- orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies. *Mod Pathol*. 2016; 29(7): 685–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
85. Arribas AJ, Rinaldi A, Mensah AA, *et al.*: DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. *Blood*. 2015; 125(12): 1922–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 86. Arribas AJ, Berton F: Methylation patterns in marginal zone lymphoma. *Best Pract Res Clin Haematol*. 2017; 30(1–2): 24–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 87. Kondo T, Oka T, Sato H, *et al.*: Accumulation of aberrant CpG hypermethylation by *Helicobacter pylori* infection promotes development and progression of gastric MALT lymphoma. *Int J Oncol*. 2009; 35(3): 547–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Lee MJ, Min BJ, Choung HK, *et al.*: Genome-wide DNA methylation profiles according to *Chlamydia psittaci* infection and the response to doxycycline treatment in ocular adnexal lymphoma. *Mol Vis*. 2014; 20: 1037–47.
[PubMed Abstract](#) | [Free Full Text](#)
 89. Zucca E, Berton F, Vannata B, *et al.*: Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. *Clin Cancer Res*. 2014; 20(20): 5207–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
 90. Ferreri AJ, Guidoboni M, Ponzoni M, *et al.*: Evidence for an association between *Chlamydia psittaci* and ocular adnexal lymphomas. *J Natl Cancer Inst*. 2004; 96(8): 586–94.
[PubMed Abstract](#)
 91. Ferreri AJ, Ponzoni M, Guidoboni M, *et al.*: Regression of ocular adnexal lymphoma after *Chlamydia psittaci*-eradicating antibiotic therapy. *J Clin Oncol*. 2005; 23(22): 5067–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 92. Vargas RL, Fallone E, Felgar RE, *et al.*: Is there an association between ocular adnexal lymphoma and infection with *Chlamydia psittaci*? The University of Rochester experience. *Leuk Res*. 2006; 30(5): 547–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. Chanudet E, Zhou Y, Bacon CM, *et al.*: *Chlamydia psittaci* is variably associated with ocular adnexal MALT lymphoma in different geographical regions. *J Pathol*. 2006; 209(3): 344–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 94. Daibata M, Nemoto Y, Togitani K, *et al.*: Absence of *Chlamydia psittaci* in ocular adnexal lymphoma from Japanese patients. *Br J Haematol*. 2006; 132(5): 651–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
 95. Ferreri AJ, Ponzoni M, Viale E, *et al.*: Association between *Helicobacter pylori* infection and MALT-type lymphoma of the ocular adnexa: clinical and therapeutic implications. *Hematol Oncol*. 2006; 24(1): 33–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 96. Mulder MM, Heddema ER, Pannekoek Y, *et al.*: No evidence for an association of ocular adnexal lymphoma with *Chlamydia psittaci* in a cohort of patients from the Netherlands. *Leuk Res*. 2006; 30(10): 1305–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 97. Gracia E, Froesch P, Mazzucchelli L, *et al.*: Low prevalence of *Chlamydia psittaci* in ocular adnexal lymphomas from Cuban patients. *Leuk Lymphoma*. 2007; 48(1): 104–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 98. Ponzoni M, Ferreri AJ, Mappa S, *et al.*: Prevalence of *Borrelia burgdorferi* infection in a series of 98 primary cutaneous lymphomas. *Oncologist*. 2011; 16(11): 1582–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 99. Roggero E, Zucca E, Mainetti C, *et al.*: Eradication of *Borrelia burgdorferi* infection in primary marginal zone B-cell lymphoma of the skin. *Hum Pathol*. 2000; 31(2): 263–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 100. Kütting B, Bonsmann G, Metz D, *et al.*: *Borrelia burgdorferi*-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. *J Am Acad Dermatol*. 1997; 36(2 Pt 2): 311–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 101. **F** Lecuit M, Abachin E, Martin A, *et al.*: Immunoproliferative small intestinal disease associated with *Campylobacter jejuni*. *N Engl J Med*. 2004; 350(3): 239–48.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 102. Al-Saleem T, Al-Mondhry H: Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. *Blood*. 2005; 105(6): 2274–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
 103. Adam P, Czapiewski P, Colak S, *et al.*: Prevalence of *Achromobacter xylosoxidans* in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. *Br J Haematol*. 2014; 164(6): 804–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
 104. Pozzato G, Mazzaro C, Crovatto M, *et al.*: Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. *Blood*. 1994; 84(9): 3047–53.
[PubMed Abstract](#)
 105. Ferri C, Caracciolo F, Zignego AL, *et al.*: Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. *Br J Haematol*. 1994; 88(2): 392–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 106. Vannata B, Zucca E: Hepatitis C virus-associated B-cell non-Hodgkin lymphomas. *Hematology Am Soc Hematol Educ Program*. 2014; 2014(1): 590–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 107. **F** Pozzato G, Mazzaro C, Dal Maso L, *et al.*: Hepatitis C virus and non-Hodgkin's lymphomas: Meta-analysis of epidemiology data and therapy options. *World J Hepatol*. 2016; 8(2): 107–16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 108. **F** Couronné L, Bachy E, Roulland S, *et al.*: From hepatitis C virus infection to B-cell lymphoma. *Ann Oncol*. 2018; 29(1): 92–100.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 109. Royer B, Cazals-Hatem D, Sibilia J, *et al.*: Lymphomas in patients with Sjögren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. *Blood*. 1997; 90(2): 766–75.
[PubMed Abstract](#)
 110. **F** Nocturne G, Mariette X: Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. *Br J Haematol*. 2015; 168(3): 317–27.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 111. Hyjek E, Isaacson PG: Primary B cell lymphoma of the thyroid and its relationship to Hashimoto's thyroiditis. *Hum Pathol*. 1988; 19(11): 1315–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
 112. Hsi ED, Singleton TP, Svoboda SM, *et al.*: Characterization of the lymphoid infiltrate in Hashimoto thyroiditis by immunohistochemistry and polymerase chain reaction for immunoglobulin heavy chain gene rearrangement. *Am J Clin Pathol*. 1998; 110(3): 327–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 113. Zintzaras E, Voulgarelis M, Moutsopoulos HM: The risk of lymphoma development in autoimmune diseases: a meta-analysis. *Arch Intern Med*. 2005; 165(20): 2337–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
 114. Bracci PM, Benavente Y, Turner JJ, *et al.*: Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. *J Natl Cancer Inst Monographs*. 2014; 2014(48): 52–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 115. Wang SS, Vajdic CM, Linet MS, *et al.*: Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. *Am J Epidemiol*. 2015; 181(6): 406–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 116. Eguchi K: Apoptosis in autoimmune diseases. *Intern Med*. 2001; 40(4): 275–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 117. Nakamura H, Kawakami A, Eguchi K: Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren's syndrome. *Transl Res*. 2006; 148(6): 281–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 118. Du M, Diss TC, Xu C, *et al.*: Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen stimulation plays a role in the clonal expansion. *Leukemia*. 1996; 10(7): 1190–7.
[PubMed Abstract](#)
 119. Spina V, Rossi D: Molecular pathogenesis of splenic and nodal marginal zone lymphoma. *Best Pract Res Clin Haematol*. 2017; 30(1–2): 5–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
 120. Algara P, Mateo MS, Sanchez-Beato M, *et al.*: Analysis of the *IgV_H* somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. *Blood*. 2002; 99(4): 1299–304.
[PubMed Abstract](#) | [Publisher Full Text](#)
 121. Berton F, Cazzaniga G, Bosshard G, *et al.*: Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. *Br J Haematol*. 1997; 97(4): 830–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 122. Conconi A, Berton F, Pedrinis E, *et al.*: Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. *Blood*. 2001; 98(3): 781–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 123. Rinaldi A, Forconi F, Arcaini L, *et al.*: Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. *Br J Haematol*. 2010; 151(5): 435–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 124. Berton F, Conconi A, Capella C, *et al.*: Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. *Blood*. 2002; 99(7): 2541–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
 125. Tierens A, Delabie J, Pittaluga S, *et al.*: Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from different marginal zone B lymphocyte subsets. *Blood*. 1998; 91(7): 2381–6.
[PubMed Abstract](#)
 126. Thieblemont C, Berton F, Copie-Bergman C, *et al.*: Chronic inflammation and

- extra-nodal marginal-zone lymphomas of MALT-type. *Semin Cancer Biol.* 2014; **24**: 33–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
127. Zibellini S, Capello D, Forconi F, *et al.*: **Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma.** *Haematologica.* 2010; **95**(10): 1792–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 128. Bikos V, Karypidou M, Stalika E, *et al.*: **An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.** *Clin Cancer Res.* 2016; **22**(8): 2032–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 129. Bikos V, Darzentas N, Hadzidimitriou A, *et al.*: **Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications.** *Leukemia.* 2012; **26**(7): 1638–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
 130. Warsame AA, Aasheim HC, Nustad K, *et al.*: **Splenic marginal zone lymphoma with VH1-02 gene rearrangement expresses poly- and self-reactive antibodies with similar reactivity.** *Blood.* 2011; **118**(12): 3331–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 131. Traverse-Glehen A, Davi F, Ben Simon E, *et al.*: **Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection.** *Haematologica.* 2005; **90**(4): 470–8.
[PubMed Abstract](#)
 132. van den Brand M, van Krieken JH: **Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review.** *Haematologica.* 2013; **98**(7): 1003–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 133. Marasca R, Vaccari P, Luppi M, *et al.*: **Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma.** *Am J Pathol.* 2001; **159**(1): 253–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 134. Craig VJ, Arnold I, Gerke C, *et al.*: **Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins.** *Blood.* 2010; **115**(3): 581–91.
[PubMed Abstract](#) | [Publisher Full Text](#)
 135. Lenze D, Berg E, Volkmer-Engert R, *et al.*: **Influence of antigen on the development of MALT lymphoma.** *Blood.* 2006; **107**(3): 1141–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 136. Greiner A, Knörr C, Qin Y, *et al.*: **CD40 ligand and autoantigen are involved in the pathogenesis of low-grade B-cell lymphomas of mucosa-associated lymphoid tissue.** *Dev Immunol.* 1998; **6**(3–4): 187–95.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Theodoros P Vassilakopoulos**

Department of Haematology, National and Kapodistrian University, Laikon General Hospital, Athens, Greece

Competing Interests: No competing interests were disclosed.

2. **Lugui Qiu**

State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research